drugset / Trial / NCT01113047

Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine

NCT01113047

Phase 3 Completed 347 enrolled Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will assess the efficacy and safety of the single pill combination of Aliskiren and Amlodipine in patients with moderate hypertension not adequately responding to a single pill combination of Olmesartan and Amlodipine. Further this study will also assess the efficacy and safety of a single pill combination of Aliskiren, Amlodipine and Hydrochlorothiazide (HCTZ) in patients with moderate hypertension not adequately responding to a single pill combination of Aliskiren and Amlodipine.

Timeline

Start
2010-05
Primary completion
2010-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg
Subject Amlodipine Other / unclassified 10 mg
Subject Hydrochlorothiazide Unknown 12.5 mg